GKAs (glucokinase activators) are promising agents for the therapy of Type 2 diabetes, but little is known about their effects on hepatic intermediary metabolism. We monitored the fate of 13 C-labelled glucose in both a liver perfusion system and isolated hepatocytes. MS and NMR spectroscopy were deployed to measure isotopic enrichment. The results demonstrate that the stimulation of glycolysis by GKA led to numerous changes in hepatic metabolism: (i) augmented flux through the TCA (tricarboxylic acid) cycle, as evidenced by greater incorporation of 13 C into the cycle (anaplerosis) and increased generation of 13 C isotopomers of citrate, glutamate and aspartate (cataplerosis); (ii) lowering of hepatic [P i ] and elevated [ATP], denoting greater phosphorylation potential and energy state; (iii) stimulation of glycogen synthesis from glucose, but inhibition of glycogen synthesis from 3-carbon precursors; (iv) increased synthesis of N-acetylglutamate and consequently augmented ureagenesis; (v) increased synthesis of glutamine, alanine, serine and glycine; and (vi) increased production and outflow of lactate. The present study provides a deeper insight into the hepatic actions of GKAs and uncovers the potential benefits and risks of GKA for treatment of diabetes. GKA improved hepatic bioenergetics, ureagenesis and glycogenesis, but decreased gluconeogenesis with a potential risk of lactic acidosis and fatty liver.
GKAs (glucokinase activators) are promising agents for the therapy of Type 2 diabetes, but little is known about their effects on hepatic intermediary metabolism. We monitored the fate of 13 C-labelled glucose in both a liver perfusion system and isolated hepatocytes. MS and NMR spectroscopy were deployed to measure isotopic enrichment. The results demonstrate that the stimulation of glycolysis by GKA led to numerous changes in hepatic metabolism: (i) augmented flux through the TCA (tricarboxylic acid) cycle, as evidenced by greater incorporation of 13 C into the cycle (anaplerosis) and increased generation of 13 C isotopomers of citrate, glutamate and aspartate (cataplerosis); (ii) lowering of hepatic [P i ] and elevated [ATP] , denoting greater phosphorylation potential and energy state; (iii) stimulation of glycogen synthesis from glucose, but inhibition of glycogen synthesis from 3-carbon precursors; (iv) increased synthesis of N-acetylglutamate and consequently augmented ureagenesis; (v) increased synthesis of glutamine, alanine, serine and glycine; and (vi) increased production and outflow of lactate. The present study provides a deeper insight into the hepatic actions of GKAs and uncovers the potential benefits and risks of GKA for treatment of diabetes. GKA improved hepatic bioenergetics, ureagenesis and glycogenesis, but decreased gluconeogenesis with a potential risk of lactic acidosis and fatty liver.
INTRODUCTION
A primary hepatic function is to rapidly clear postprandial glucose that reaches the liver through the portal vein [1] . This function, involving enhanced glycolysis and glycogen synthesis but decreased gluconeogenesis, is essential to overall glucose homoeostasis [1] [2] [3] [4] [5] . GK (glucokinase), which mediates the initial step of hepatic glucose metabolism, clearly is pivotal to this role. A network of GK-containing cells is present throughout the body [1, 4] , most prominently in hepatocytes and pancreatic β-cells [3, 4] . This enzyme plays a dual role: in β-cells it is a glucose sensor and in hepatocytes it serves as a pacemaker for glucose storage. The centrality of GK in body glucose homoeostasis has made it a promising drug target for diabetes therapy [3] [4] [5] . Enormous strides have been made to develop drugs that activate GK [1] [2] [3] [4] [5] . These efforts have been very successful, including limited human clinical trials [6] . However, few of the newly developed GKAs (GK activators) have reached the point of practical clinical application [3, 4] .
Approximately 99 % of GK in the body is located in the liver [4] and hepatic carbohydrate metabolism is profoundly impaired in Type 2 diabetes. Thus a potentially key therapeutic goal is to modify body glucose homoeostasis by utilizing GKAs to modulate GK activity. Little is know about the action of GKAs on hepatic intermediary metabolism, including the effects on PDH (pyruvate dehydrogenase), PC (pyruvate carboxylase), the TCA (tricarboxylic acid) cycle, hepatic energy potential, ureagenesis and lipogenesis. We hypothesized that stimulation of glycolysis by GKA will result in a widespread alteration of hepatic metabolic pathways and intermediary metabolism. Stimulation of GK should increase glycolysis and production of pyruvate, thereby favouring incorporation of glucose carbon into the pathways and metabolic cycles illustrated in Figure 1 . In the present study we investigated a new GKA, Piragliatin [3] [4] [5] , by deploying [U- 13 C 6 ]glucose as a tracer in a liver perfusion system to evaluate to what extent activation of GK and stimulation of glycolysis would influence: (i) the hepatic redox state; (ii) flux through PC, PDH or the TCA cycle; (iii) glycogen synthesis; (iv) gluconeogenesis; and/or (v) synthesis of amino acids, NAG (N-acetylglutamate) and ureagenesis.
Glycolysis articulates with a complex metabolic network ( Figure 1 ). Perfusing the structurally intact liver with a solution similar to portal blood thereby affords a model with which to investigate the action of GKA on hepatic glucose handling. We perfused liver in an antegrade mode with or without Piragliatin at a near-maximal concentration [6, 7] . We used livers from fed animals in order to simulate physiological conditions and to avoid hormonal effects, such as an increase of the glucagon/insulin ratio following an overnight fasting state. A separate series of experiments was carried out with isolated hepatocytes in order to determine whether GKA acts specifically on GK or whether it has 'off-target actions' directly influencing the metabolism of pyruvate, for example by affecting the PDH and/or PC activity or the cytosolic malic enzyme [8] .
The present study provides the first comprehensive insight into the widespread action of GKA on glycolysis and associated hepatic metabolic pathways in the postprandial state. The findings show that GKA has many actions, including improved bioenergetics, up-regulation of hepatic glycogenesis or ammonia detoxification through ureagenesis, increased generation of lactate and decreased gluconeogenesis. This scheme illustrates the potential action of GKAs on the coupling between glycolysis, glycogen synthesis, pentose phosphate shunt (PPS) and nucleotide synthesis, the TCA cycle, the generation of citrate and the resulting lipid synthesis, the generation of amino acids and detoxification of ammonia through the urea cycle. Pyruvate, the end product of glycolysis, is converted into lactate, malate or alanine in the cytosol and/or to acetyl-CoA plus CO 2 in the mitochondrion. Acetyl-CoA may be (a) metabolized in the TCA cycle, (b) utilized for NAG synthesis, and/or (c) converted into ketone bodies. In addition, pyruvate may enter the TCA cycle through PC generating oxaloacetate (anaplerosis). Oxaloacetate may be transaminated to aspartate and/or may react with acetyl-CoA to form citrate, thereby facilitating formation of 2-oxoglutarate and glutamate (cataplerosis). Citrate may be transported to the cytosol and metabolized through citrate lyase to malonyl-CoA, leading to enhanced lipid synthesis. The production of glutamate and acetyl-CoA provides substrates for mitochondrial NAG synthesis, and thus activates carbamoyl-phosphate synthetase-1 and up-regulates citrulline and urea synthesis. In addition, the following enzymes participate in the metabolic pathways considered in the present study: (1) PDH; (2) PC; (3) glutamate dehydrogenase; (4) NAG synthetase; (5) ornithine aminotransferase; (6) carbamoyl-phosphate synthetase-1; (7) ornithine transcarbamoylase; (8) aspartate-oxaloacetate aminotransferase; (9) malic enzyme; (10) phosphohexose isomerase; (11) phospho-fructokinase-1; (12) aldolase; (13) 
EXPERIMENTAL

Materials and animals
Male Sprague-Dawley rats (Charles River) were fed a standard rat chow diet ad libitum. Chemicals were of analytical grade and obtained from Sigma-Aldrich. Enzymes and cofactors for the analysis of adenine nucleotides, β-OH-butyrate, acetoacetate, NADH, NAD + , urea, lactate, pyruvate and ammonia were obtained from Sigma. 13 C-labelled glucose, pyruvate and lactate or 15 NH 4 Cl, 99 MPE (mole percentage excess), were from Isotec and Piragliatin (RO4389620) from Hoffman-La Roche.
Experiments with liver perfusions
Livers from fed male rats were perfused in the non-recirculating mode and antegrade flow of 3-3.5 ml. g − 1 · min − 1 as described previously [9] . Before initiation of the experiment, the liver was washed with Krebs saline plus 0.1 % DMSO and glucose (5 mM) as a metabolic fuel (pH 7.4). The perfusate was continuously gassed with 95 % O 2 /5 % CO 2 and pO 2 (in the influent and effluent media) was monitored throughout. After 15 min of conditioning with basic medium containing 0.1 % DMSO and 5 mM glucose in Krebs buffer, pH 7.4, the perfusate was replaced with one containing 0.1 % DMSO, 5 mM [U- 13 C 6 ]glucose, 0.3 mM 15 NH 4 Cl and 1 mM glutamine (Medium-A). After 30 min of perfusion with Medium-A, 3 μmol · l − 1 Piragliatin was added (Medium-A + GKA), and perfusion was continued for an additional 30 min. The concentration of Piragliatin was chosen on the basis of previous studies demonstrating that this drug reaches a near-maximal effect within 2-3 min at 2-3 μmol · l − 1 [6] . Independent control perfusions without GKA were performed with Medium-A for 50 min after conditioning the liver for 15 min.
In each perfusion, samples were taken from the influent and effluent media for measurement of 13 CO 2 release, enzymatic assays, GC (gas chromatography)-MS or LC (liquid chromatography)-MS analyses as indicated [9, 10] . At the end of perfusion the liver was freeze-clamped with aluminum tongs pre-cooled in liquid N 2 . The frozen liver was ground into a fine powder and kept at − 80
• C. One portion was extracted with perchloric acid, neutralized with KOH, and used for metabolite determination and measurement of 13 C enrichment with GC-MS or determination of a positional 13 C isotopomer with NMR.
Studies with isolated hepatocytes
Hepatocytes were prepared from liver of fed rats by a twostep procedure as described previously [11, 12] . Briefly, after washing the liver with oxygenated Krebs buffer (pH 7.5), isolated liver was perfused for 10-15 min with 0.03 % collagenase in Krebs buffer (37 • C, pH 7.5). The liver was then transferred to a flask and the exterior membrane was disrupted. Hepatocytes were filtered through 250 μm mesh. (5) . At the end of incubation, an aliquot (200-300 μl) was taken for measuring the release of 13 CO 2 . Immediately afterwards, incubation was stopped with HClO 4 (70 %). Metabolite measurements were performed using neutralized extracts. Three to five independent experiments were carried out per series.
LC-MS, GC-MS or NMR methodology
Measurement of 13 C-isotopomer enrichment was performed on either an Agilent Triple Quad 6410 mass spectrometer combined with an Agilent LC 1290 Infinity or Hewlett-Packard 5971 MSD (mass selective detector), coupled with a 5890 HP-GC, GC-MS Agilent System (6890 GC/5973 MSD) or a Hewlett Packard HP-5970 MSD using electron impact ionization with an ionizing voltage of − 70eV and an electron multiplier set to 2000V. The following metabolites were analysed.
Measurement of
13 C-labelled aldose or aldose-P
We used the LC-MS system to determine the 13 C isotopomers as well as the concentration by an isotope-dilution approach. 13 C-labelled glucose, G6P (glucose 6-phosphate) and GA3P (glyceraldehyde 3-phosphate) were prepared as described previously [13] . Briefly, 50-200 μl of tissue extract were dried, and thereafter 50 μl of NaOH (0.3 M) and 50 μl of PMP (1-phenyl-3-methyl-5-pyrazolone) (0.5 M) were added. The mixture was incubated for 30 min at 70
• C. After cooling to room temperature (25 • C), 50 μl of 0.3 M HCl and 0.5 ml of H 2 O were added. The excess of PMP was removed by two extractions with ethyl acetate. The water fraction was dried down and dissolved in 200 μl of LC solvent A (water with 0.1 % formic acid). A 1 μl volume of derivatized sample was injected into the LC-MS instrument for analysis. The LC gradient was as follows: Solution A, water with 0.1 % of formic acid; Solution B, acetonitrile with 0.1 % formic acid and 0.005 % TFA (trifluoroacetic acid). Running program: 0-1 min, 25 % B; 1-4 min, 28 % B; 5-7 min, 100 % B; 7-9 min, 0 % B; and 9-10 min, 25 % B. The flow rate was 0.5 ml · min − 1 throughout. The retention time for G6P was 2.2 min, for glucose 2.95 min and for GA3P 3.10 min. The column used was Poroshell 120 EC-C 18 , 4.6 mm×50 mm with a particle size of 2.7 μm. We followed the precursorproduct links for the aldoses studied with a collision energy of 30 V and fragmentor voltage of 150 V. For glucose in MRM (multiple reaction monitoring) mode, we measured ionpairs 511-175, 512-175, 513-175, 514-175, 515-175, 516-175 and 517-175 for determination of M0, M1, M2, M3, M4, M5 and M6 respectively (containing one to six 13 C atoms above M0, the natural abundance). For G6P, we measured ion-pairs 591-175, 592-175, 593-175, 594-175, 595-175, 596-175 and 597-175 for determination of M0, M1, M2, M3, M4, M5 and M6 respectively (containing one to six 13 C atoms above M0, the natural abundance). For GA3P we measured ion-pairs at 501-175, 502-175, 503-175 and 504-175 for determination of M0, M1, M2, M3 respectively (containing one to three 13 C atoms above M0, the natural abundance). After determining the 13 C enrichment in G6P and GA3P, the samples were spiked with known concentrations of unlabelled G6P and GA3P, then samples were analysed by LC-MS to determine the dilution of 13 C enrichment for calculation of the metabolite levels.
Measurement of 13 CO 2 release
The production of 13 CO 2 during liver perfusion or following incubation of isolated hepatocytes was monitored as follows: 100-200 μl samples were placed into autosampler tubes. The capped tubes with sample were filled with helium to remove any atmospheric CO 2 . Then, 100 μl of 20% phosphoric acid was injected through the stopper to liberate the CO 2 . Isotopic enrichment in 13 CO 2 was determined by an isotope-ratio mass spectrometer (Thermoquest Finnigan Delta Plus) using an m/z ratio of 45/44.
Measurement of 13 C-labelled glycogen synthesis
A separate portion of the frozen liver after perfusion was ground into powder and samples were incubated in the presence or absence of amyloglucosidase as described previously [14] . The liberated glucose from glycogen was determined by glucose oxidase assay [15] . The background glucose content was subtracted to obtain the tissue glycogen content, and 13 C enrichment in glucose was determined by LC-MS as described above. Results obtained were expressed as μmol of 13 C-labelled glucose released from glycogen per g of wet mass of liver.
Measurement of 13 C-labelled isotopomers in amino or organic acids
For measurement of the 13 C enrichment in amino acids or organic acids, samples were prepared as described previously [9] . Briefly, an aliquot (500 μl) of effluent, liver or hepatocyte extracts was purified by passage through an AG-1 column (Cl − : 100-200 mesh; 0.5 cm×2.5 cm) for separation of organic acids and glutamate and aspartate residues or by passage through an AG-50 column (H + : 100-200 mesh) for separation of alanine, serine, glycine and glutamine residues and urea. Then, samples were converted into the t-butyldimethylsilyl derivatives [9, 10] . Isotopic enrichment in [
13 C]alanine isotopomers was monitored using ions at m/z 260, 261, 262 and 263 for M0, M1, M2 or M3 (containing one to three 13 C atoms above M0, the natural abundance) respectively. Isotopic enrichment for [ 13 The concentration and 13 C enrichment in NAG isotopomers in liver extracts were determined using LC-MS. A 200 μl volume of sample was dried down, mixed with 200 μl of 3 M butanolic HCl and heated at 60
• C for 15 min. Then, samples were cooled to room temperature, dried and mixed with 0.5 ml of water. The derivatized NAG was extracted with 2 ml of ethyl acetate. The organic fraction was dried under a stream of N 2 , and then reconstituted with 200 μl of 0.1% formic acid in H 2 O. Finally, samples were filtered and 1 μl was injected into the LC instrument. The chromatogram gradient was as follows: Solution A, 0.1 % formic acid in H 2 O; Solution B, acetonitrile with 0.1 % formic acid and 0.005 % TFA. Times: 0-1 min, 25 % B; 1-2 min, 35 % B; 2-3 min, 45 % B; 3-4 min, 55 % B; 4-5 min, 65 % B; 5-6 min, 75 % B; 6-7 min, 85 % B; and 7-9 min, 100 % B. The flow rate was 0.5 ml · min − 1 throughout. The retention time of the NAG derivative was 3.92 min. The column used was Poroshell 120 EC-C18, 4.6 mm×50 mm with a particle size of 2.7 μm. The ion-pairs monitored were 302-228, 303-229, 304-230, 305-231, 306-232, 307-233, 308-234 and 309-235 for determination of M0, M1, M2, M3, M4, M5, M6 and M7 respectively (containing one to seven 13 C atoms above M0, i.e. five carbons from glutamate and two carbons from acetyl-CoA). This link reflects the loss of a fragment weighing 73 (i.e. CH 3 -CH 2 -CH 2 -CH 2 -OH). After the initial measurement of 13 C enrichment in NAG isotopomers, the samples were spiked with a known amount of NAG for determination of the NAG concentration by isotope dilution [10] . The production of 15 N-labelled urea isotopomers (containing one or two 15 N atoms) from 15 NH 4 Cl and its output in the perfusate were determined as described previously [16] .
NMR analysis
To further evaluate the action of GKA on positional isotopomers in the intermediary metabolites, a portion (approximately 1 g of wet mass) of the neutralized liver extracts was analysed by 1 H NMR, 13 C NMR and 31 P NMR methodology using a Bruker Avance III 400 wide bore equipped with a Hewlett Packard workstation running the Bruker Topspin TM NMR software. The chemical shifts of 13 C signals were measured relative to the resonance of trimethylsilylpropionic acid at − 2.7 p.p.m. in the 13 C-NMR spectra. Data acquisition and calculation of percentage 13 C enrichment in various glutamate carbons were performed as described in [10, 17] . P i or compounds containing phosphate were identified and their levels were measured relative to the resonance of methylene diphosphonate (16.7 p.p.m.) contained in an external capillary [10, 17] .
Measurement of metabolite levels
The concentration of amino acids was determined with an Agilent 1260 Infinity LC system, utilizing pre-column derivatization with o-phthalaldehyde [18] . The levels of ammonia and urea were measured as described in [9, 10, 16] , those of ATP as in [19] , and those of of ADP and AMP as in [20] . We also measured the level of NAD and NADH as described in [21] using a BioVision quantification kit, levels of lactate [22] , pyruvate [23] , acetoacetate and β-OH-butyrate [24] , malate [25] , glucose [15] , glycogen [14] and fructose 1,6-bisphosphate [26] , and levels of triglycerides in liver extract using an Infinity TM Triglycerides Reagent kit.
Calculations and statistical analyses
Production and output of 13 
C-labelled mass isotopomers or [ 15 N]urea
During liver perfusions, the rate of uptake or the output of metabolites was determined by the measurement of metabolite concentration in the influent and effluent (nmol · ml − 1 ), normalized to the flow rate (ml · min − 1 ) and liver wet mass (g) as described previously [9, 16] . 13 C enrichment in 13 C-labelled mass isotopomers is expressed as MPE, which is the molar fraction (%) of analyte containing 13 C atoms above natural abundance. The MPE of an individual 13 Clabelled mass isotopomer (containing i 13 C atoms, i.e. in the case of glutamate i = 1-5, for citrate i = 1-6 etc.) was calculated as in [27, 28] .
where A M and A M + i represents the peak area from LC-MS or GC-MS ions corrected for natural abundance as described in [27, 29] , and corresponding to the unlabelled (M0) and 13 Clabelled (M + i) mass isotopomer respectively. The output of 13 C-labelled mass isotopomer was calculated by the product of (MPE/100) multiplied by the concentration (nmol · min − 1 per g of wet mass) and is expressed as nmol of 13 C-labelled metabolite · min − 1 per g of wet mass. Similarly, the concentration of 13 C-labelled mass isotopomer in the liver was calculated by the product of (MPE/100) multiplied by the concentration (nmol · g − 1 of wet mass) and is expressed as nmol of 13 C-labelled metabolite per g of wet mass. The output of 13 CO 2 (nmol · min − 1 per g) was calculated by the product of [ 13 CO 2 enrichment (atom percentage excess)/100] multiplied by flow rate (ml · min − 1 per g) multiplied by 25 mM (i.e. the concentration of NaHCO 3 in the perfusate). The output of 15 N-labelled urea isotopomers was calculated as indicated in [9, 16] .
Glycogen synthesis
Hepatic glycogen synthesis may be mediated through a direct pathway from glucose and an indirect pathway from gluconeogenic precursors (lactate, pyruvate etc.) [30, 31] . In the present study, the synthesis of glycogen from the perfusate [U- 13 
Because the direct measurement of NAD + , NADH, NADP + and NADPH is not informative in terms of the control of metabolism, the free cytosolic NAD + /NADH and NADP + /NADPH ratios were calculated from metabolite concentrations and the equilibrium constants of LDH (lactate dehydrogenase) and malic enzyme as described in [32, 33] − 2 M). The CO 2 concentration was taken as 1.16 mM [32] . The mitochondrial NAD + /NADH ratio was calculated as follows:
Each series of experiments was repeated three times with an individual liver perfusion system as outlined above. Statistical analysis was carried out using Prism 5 software. A Student's t test or ANOVA test was employed to compare two groups or differences among groups as needed. 
RESULTS
O 2 consumption following near-maximal GK activation with Piragliatin
, n = 3) between 10 and 35 min (55-75 min of perfusion). The plateau levels of O 2 consumption in both study groups indicate that equilibrium is reached during the course of liver perfusion. The increased O 2 consumption within 3-5 min following supplementation of Piragliatin also demonstrates an immediate and direct response to the drug, probably subsequent to increased glycolysis and oxidative phosphorylation.
[U- 13 C 6 ]glucose uptake and metabolite output following GK activation with Piragliatin Table 1 summarizes rates of [U- 13 C 6 ]glucose uptake and 13 Clabelled metabolite output during perfusion with or without GKA. In the perfusion with GKA, there was a near-4-fold increased The rate of glucose uptake was determined by the differences between glucose concentrations in the influent and effluent (nmol · ml − 1 ), normalized to the flow rate (ml · ml − 1 ) and liver wet mass (g), as described previously [9, 16] . The rates of 13 C-labelled metabolite output are the steady-state values obtained between 30 and 65 min of perfusion without GKA (Control) or 55-75 min of perfusion with GKA [( + ) GKA], as presented in Figures 3 and 4 . These rates were determined by measuring of metabolite concentrations in the effluent (nmol/ml), normalized to the flow rate (ml · ml − 1 ) and liver wet mass (g), as in [9, 16] . Experimental details are as described in the legends to Figure 2 . Results are means + − S.D. of three livers per group. P values were determined by Student's t test using Prism 5 software. uptake of [U- 13 C 6 ]glucose compared with controls ( Table 1 ). The hepatic uptake of glucose is in line with the notion that the liver switches from an organ of net glucose output to one of net glucose uptake in response to a 'threshold' concentration of portal venous glucose (approximately 5.5 mM) [30] . The increased uptake of [U- 13 C 6 ]glucose by GKA was accompanied by a 3-fold increased output of 13 CO 2 (Table 1 and Figure 3A ) and an even larger increase of 13 C-labelled pyruvate and lactate output (Table 1 , Figures 3B and 3C , and Supplementary Figure S1 at http://www. BiochemJ.org/bj/444/bj4440537add.htm). Similarly, with the addition of GKA there was a 6-7-fold increased outflow of 13 C-labelled alanine (Table 1, Figure 4A , and Supplementary Figure S2 at http://www.BiochemJ.org/bj/444/bj4440537add. htm) accompanied by approximately 30 % lower output of 13 Clabelled glutamate ( Figure 4B ). These results demonstrate that the action of GKA on hepatic metabolism occurred within 3-5 min following exposure to the drug. Liver perfusions were carried out as detailed in the legend to Figure 2 . The output of 13 C-labelled alanine or glutamate is the sum of the 13 C enrichment (MPE/100) in M2 and M3 ( 13 C isotopomers of alanine) and M1, M2, M3, M4 and M5 ( 13 C isotopomers of glutamate) multiplied by total output (nmol · min − 1 per g of wet mass). Results are means + − S.D. for three independent liver perfusions per study group. *P < 0.05, compared with control.
Metabolite profiles, energy potential and redox state of liver tissue following near-maximal GK activation with Piragliatin
The results in Table 2 indicates an increase (P = 0.03) upon stimulation of glucose metabolism, a finding in accordance with the modest increase of adenylate energy charge (P = 0.06). These results imply that GKA improved the energy metabolism in the liver, since both the ATP/ADP ratio and adenylate energy charge are indicative of the availability of high-energy phosphates for metabolic and functional needs. Table 3 presents levels of intermediary metabolites in freezeclamped livers at the end of perfusion. We found a significant accumulation of lactate (P = 0.02) and a slight increase in Table 2 pyruvate (P = 0.06) in the presence of GKA, but strikingly constant levels of citrate, malate, acetoacetate, β-OH-butyrate, NAD + or NADH (Table 3) . However, the level of triglycerides was increased marginally (P = 0.07) ( Table 3 ). In addition, the levels of G6P and GA3P rose significantly with little change in the levels of fructose 1,6-bisphosphate. The 31 P-NMR spectra of freeze-clamped liver corroborate the LC-MS measurement and demonstrate a higher peak of G6P following GKA (Supplementary Figure S3 at http://www. BiochemJ.org/bj/444/bj4440537add.htm). Similarly, 31 P-NMR spectra show an approximately 2-fold higher peak of glycerol 3-phosphate in the liver when GKA was present.
The ratios of NAD + /NADH as calculated from the levels of these cofactors show little change following GKA (Table 3 ). In addition, the free cytosolic NAD + /NADH and NADP + /NADPH ratios were calculated from concentrations of pyruvate, lactate or malate, and mitochondrial NAD + /NADH from concentrations of β-OH-butyrate and acetoacetate [32, 33] . These results demonstrate that GKA has little effect on cytoplasmic NADP + /NADPH or cytoplasmic and mitochondrial NAD + /NADH (Table 3) , suggesting a minor effect on the redox state. Figure 5 represents the GC-MS analysis of 13 C-isotopomer profiling of lactate (panel A), citrate (panel B) and malate (panel C) in liver extracts. These results demonstrate that GKA remarkably increased 13 C enrichment (MPE) in all mass isotopomers of these intermediates compared with control perfusions. The results in Figures 5(D)-5(F) demonstrate that the incorporation of [U- 13 C 6 ]glucose carbon into lactate, citrate and malate was approximately 5-fold higher following perfusion with GKA compared with controls, and that the generation of 13 Clabelled lactate is the primary 'sink' into which glucose carbon flows following stimulation of glycolysis by GKA. The 13 C 3 -lactate (M3) isotopomer was the major product of glycolysis, and was probably derived from [U- 13 C 3 ]pyruvate mediated through the LDH reaction. Furthermore, a readily detectable amount of doubly 13 C-labelled lactate (M2) was observed with or without GKA ( Figure 5A ). M2 lactate can not be produced from [U- 13 C 6 ]glucose through glycolysis alone and it may be generated through the sequence glycolysis→TCA cycle→cytosolic malic enzyme→gluconeogenesis, followed by glycolysis of newly formed 13 C-labelled glucose. An additional possibility is that the pyruvate cycling through pyruvate kinase may be responsible for production of M2 lactate.
C-isotopomer profiling in liver tissue following GK activation with Piragliatin
Figures 5(B) and 5(C) depict the 13 C-isotopomer profile of citrate and malate, the chief metabolites produced through incorporation of 13 13 C-labelled citrate and malate in livers perfused with GKA, but to a much lesser extent than that of lactate. Figure 6 represents the 13 C isotopomer profile of alanine, serine or glycine in the liver. The M3 labelling pattern for the [ 13 C]alanine isotopomer ( Figure 6A ) was generally similar to that of lactate ( Figure 5A ), the alanine having formed from transamination of [U- 13 C 3 ]pyruvate. Activation of GK significantly increased the generation and accumulation of 13 C-labelled alanine and resulted in a marginal elevation of serine and glycine from [U- 13 C 6 ]glucose ( Figures 6D-6F respectively) . Figure 7 represents the 13 C mass isotopomer profiles of glutamate, glutamine and aspartate. 13 C mass isotopomers of glutamate and aspartate ( Figures 7A and 7B ) are cataplerotic metabolites deriving from the TCA cycle [27, 28] . The M2, M3, M4 and M5 13 C mass isotopomers of glutamine resemble that of glutamate ( Figure 7C ). Because 15 NH 4 Cl was added to the perfusate, the M1 isotopomer of glutamine must have been derived from 15 NH 4 Cl and unlabelled glutamate in hepatocytes. The sum of 13 C mass isotopomer production of glutamate, aspartate and glutamine from [U- 13 C 6 ]glucose is presented in Figures 7(D) -7(F) respectively and demonstrates a significantly increased generation of these amino acids following GKA-induced stimulation of hepatic glycolysis.
The positional 13 C isotopomers in liver tissue: measurement with 13 
C-NMR
We found that the LC-MS and GC-MS data ( Figures 5-7) were corroborated by 13 C-NMR analysis (Supplementary Figure  S4 at http://www.BiochemJ.org/bj/444/bj4440537add.htm). 13 C-NMR spectra demonstrate higher peaks of 13 C isotopomers of lactate, alanine, serine, glycine, malate, glutamate and aspartate with GKA (Supplementary Figure S4B) compared with controls (Supplementary Figure S4A) . The 13 C-coupling pattern of C-3 and C-2 of lactate and alanine were doublet and quartet, indicating that lactate and alanine were largely labelled at all three carbon positions. This is consistent with the abundance of the M3 mass isotopomers of lactate and alanine as determined by GC-MS (Figures 5A and 6A) . Similarly, the doublet or multiplet pattern of C-2, C-3 and C-4 of glutamate, C-2, C-3 of aspartate or C-3 of malate are in agreement with the GC-MS measurement of 13 C mass isotopomer profile (Figures 5-7) . Of special interest is the observation that the peaks corresponding to C-3 and C-2 glutamate isotopomers are higher than the C-4 isotopomer. Glutamate is labelled at the C-4 and C-5 positions through the forward cycle reactions following incorporation into the TCA cycle of [ 13 C 2 ]acetyl-CoA, the product of PDH. However, glutamate is labelled at C-2 and C-3 mainly through anaplerosis by pyruvate carboxylation. In perfusions with GKA, the percentage 13 C enrichment in C-2, C-3 and C-4 was approximately 9, 16 and 9 respectively. In controls without GKA, the percentage 13 C enrichment in C-2, C-3 and C-4 was approximately 2, 3 and 1 respectively. Thus the percentage enrichment of 13 C isotopomers indicate that: (i) the incorporation of 13 C-labelled pyruvate into the TCA cycle through the PC was remarkably higher compared with the incorporation of [ 13 C 2 ]acetyl-CoA, the product of PDH activity; and (ii) the incorporation of 13 C-labelled pyruvate into the TCA cycle and the flux of carbons through the cycle were elevated in livers perfused with GKA compared with control. The 13 C-NMR spectra also revealed important information regarding the relationship between hepatic glycolysis and glutamine metabolism. C-3 of glutamine is mainly singlet in control studies (Supplementary Figure S4) , suggesting that the glutamine peak was largely related to the natural abundance of 13 C in unlabelled glutamine added to the perfusate. However, following perfusion with GKA, C-2, C-3 or C-4 of glutamine resembled the 13 C pattern of glutamate. It is likely that an increase in glycolysis induced by GKA together with increased availability of 13 C-labelled glutamate and ATP led to increased synthesis of 13 C[glutamine] from 13 C[glutamate] in the perivenous hepatocytes [34, 35] . Figure 8 (A) indicates that the total glycogen in freezeclamped liver at the end of perfusion was slightly elevated following perfusion with GKA, being approximately 161 + − 38 and 180 + − 18 μmol · g − 1 of wet mass (means + − S.D., n = 3) in liver perfused with or without GKA respectively. Figure 8 (B) demonstrates that GKA significantly (P = 0.045) stimulated the synthesis of glycogen from perfusate [U- 13 C 6 ]glucose as determined by the appearance of [U- 13 C 6 ]glucose in glycogen. However, the synthesis of glycogen with M3 (indirect pathway) was significantly (P = 0.02) decreased by GKA as determined by the appearance of [ 13 C 3 ]glucose (M3) in hepatic glycogen following perfusion with GKA ( Figure 8B ). The amount of [U- 13 C 6 ]glucose derived through the amyloglucosidase reaction was 3.97 + − 1 and 2.3 + − 1.1 μmol · g − 1 of wet mass liver in perfusions with or without GKA respectively (means + − S.D., n = 3, P = 0.04). The amount of [ 13 C 3 ]glucose was 0.45 + − 0.1 and 0.71 + − 0.11 μmol · g − 1 of wet mass liver in perfusions with or without GKA respectively (means + − S.D., n = 3, P = 0.02) ( Figure 8B ). Thus, in liver perfused with GKA, approximately 87 % and 13 % of glycogen synthesis was derived from glucose and a 3-carbon precursor respectively. In the perfusion without GKA, the fraction of direct and indirect pathways was approximately 77 % and 23 % respectively. In addition, the 13 C-NMR spectra demonstrate a remarkably higher [
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13 C]glycogen peak (C1 glucosyl at approximately 100 p.p.m.) in liver following perfusion with GKA ( Supplementary  Figure S4) , indicating that GKA augmented the synthesis of glycogen from 13 C 6 -labelled glucose. The finding that GKA increased the direct and decreased the indirect pathway of glycogen synthesis is further supported by the observation that when liver was perfused only with 13 C-labelled lactate plus pyruvate the rate of gluconeogenesis from these 3-carbon precursors was decreased by GKA (Supplementary Figure S5 at http://www.BiochemJ.org/bj/444/bj4440537add.htm).
GKA increases hepatic NAG and stimulates urea synthesis
The results in Figure 9 (A) indicate that the total [NAG] in the liver was increased in perfusions with GKA. This increase is mainly due to a significantly augmented (P = 0.028) synthesis of 13 C-labelled NAG. Because NAG is synthesized from acetylCoA and glutamate [12] , the 13 C mass isotopomers profile for NAG indicates that [
13 C]NAG was generated from [ 13 C 2 ]acetylCoA and the various 13 C mass isotopomers of glutamate, as depicted in Figure 7(A) . Thus, consistent with the augmented production of 13 C-labelled metabolites by GKA (Figures 5-7) , the increased production of 13 Figure 9C ). The data suggest that the stimulation of glycolysis by GKA furnished both acetyl-CoA and glutamate for synthesis of NAG, and consequently up-regulation of hepatic ureagenesis.
Experiments with isolated hepatocytes
To determine whether GKAs act on the multiple pathways of pyruvate metabolism (Figure 1 ), experiments were carried out using isolated hepatocytes incubated with [ [1- 13 C]pyruvate into the TCA cycle through PC, resulting in the generation of M1 oxaloacetate and then M1 aspartate. M1 citrate is formed through the first turn of the TCA cycle, whereas M1 malate is formed through malic enzyme [8, 27, 28] . In experiments with [3- 13 C]pyruvate, M1 13 C-acetyl-CoA is formed through PDH and 13 CO 2 is released only through the TCA cycle. In this series of experiments, the release of 13 CO 2 was approximately 4.8 or 5.1 μmol · mg − 1 hepatocyte protein without or with GKA respectively. Incubation with GKA had little effect on either the concentration or enrichment (MPE) of 13 C mass isotopomers of citrate, glutamate, succinate, malate and aspartate (results not shown). Thus when an equimolar amount of pyruvate (i.e. 5mM) was used, there was little difference in the release of 13 CO 2 or in the generation of M1 mass isotopomers of aspartate, citrate and malate, suggesting that GKA has no direct effect on the activity of PDH, PC or malic enzyme.
To explore whether Piragliatin has 'off-target' effects, experiments were carried out with 5 mM [U- 13 C 6 ]glucose as the sole substrate. We first determined the time course of GKA action. The results indicated that within the first 2 min of incubation, there was a near-2-fold increase in 13 CO 2 release from 5 mM [U- 13 C 6 ]glucose (results not shown), in agreement with previous studies demonstrating an immediate activation of GK when β-cells were exposed to Piragliatin [2] [3] [4] . A separate series of experiments demonstrated a 2-fold increased release of 13 hepatocyte protein (means + − S.D., n = 4) without or with GKA respectively ( Figure 10A ). Cumulatively, the results indicate that the addition of 3 μmol · l − 1 Piragliatin activated GK and stimulated glycolysis in experiments with isolated hepatocytes in a manner similar to that observed in a liver perfusion system.
It remained unresolved whether the GKA effect on gluconeogenesis represents an indirect effect, perhaps secondary to the induction of changes in levels of metabolites, or a direct effect that corresponds to GKA-induced modification of critical enzymatic steps in the gluconeogenic pathway. This question was addressed in experiments with isolated hepatocytes incubated with 5 mM [3- 13 C]pyruvate as a precursor. LC-MS analysis indicated the production of 13 C-labelled glucose mainly at one (M1) or two (M2) carbons. The sum of M1 and M2 13 C-labelled glucose produced was 108 + − 9 and 144 + − 7 (means + − S.D.) nmol · mg − 1 hepatocyte protein with or without GKA respectively ( Figures 10B and 10C ), indicating that GKA decreased gluconeogenesis from pyruvate. These findings and those noted with liver perfusion indicate that GKA reduced gluconeogenesis ( Figure 10 and Supplementary Figure S5) , even in the absence of added glucose.
DISCUSSION
The contribution of the present study to understanding the action of GKA on hepatic metabolism GK, a unique isoform of the hexokinase enzymes, phosphorylates D-glucose and other hexoses [1, 4] . GK activators were recently identified as new promising drugs targeting Type 2 diabetes [1] [2] [3] [4] . The basic enzymology, structure and mechanism of action of GK have been described [3, 4, 7] . The effectiveness of GKA is determined by the level of free cytosolic GK, by the ability of the drug to dissociate the enzyme from a nuclear regulatory protein [GKRP (GK regulatory protein)-GK complex] [7] and, perhaps most importantly, by the level of free intracellular glucose. A network of GK-containing cells contributes to glucose homoeostasis, the most important regulators being the pancreatic β-cell and the liver, which contains approximately 99 % of total body GK [3, 4] . Despite the key role of GK, knowledge about the effects of GKAs on hepatic intermediary metabolism and metabolic pathways remains limited [1, 3, 4, 7] . There has been little research on the impact of GKA treatment on flux through PDH, PC or the TCA cycle, the hepatic redox or energy states, ureagenesis or lipogenesis. We have investigated how a new GKA, Piragliatin [2, 3, 4] , influences glycolysis and related pathways of hepatic glucose metabolism. We chose Piragliatin because of its known efficacy in Type 2 diabetics [6] . In accordance with our hypothesis, the present findings demonstrate that GKA stimulation of glycolysis had wide effects on the hepatic metabolic network, including: (i) increased hepatic glucose uptake (Table 1 ) and subsequent augmentation of the output of 13 CO 2 , 13 C-labelled lactate and alanine, the products of glycolysis (Table 1 , and Figures 3 and 4A) ; (ii) augmented anaplerosis and increased flux through the TCA cycle and cataplerosis of glutamate and aspartate ( Figures 5-7) ; (iii) increased glycogen synthesis through the direct pathway and evidence for decreased gluconeogenesis and synthesis of glycogen through the indirect pathway (Figures 8 and 10 , and Supplementary Figure S5) ; (iv) increased synthesis of NAG and augmented ureagenesis ( Figure 9) ; (v) a tendency towards elevation of hepatic triglycerides (Table 3) ; and (vi) improved hepatic O 2 consumption, energetic state and phosphorylation potential ( Figure 2 and Table 2 ). Taken together, the results of the present study provide the deepest insight to date into the action of GKA on hepatic intermediary metabolism, in particular the recognition of close coupling between hepatic glycolysis and nitrogen metabolism, as illustrated in Figure 11 .
The GKA-induced alteration in hepatic intermediary metabolism is accompanied by a near-3-fold increase in glucose uptake (Table 1) . These results indicate that approximately 50 % and 30 % of glucose uptake was accounted for by the output of 13 C-labelled pyruvate, CO 2 , lactate and alanine in perfusions with or without GKA respectively ( Table 1 ). The remainder of glucose uptake was probably used for synthesis of glycogen, other amino acids, organic acids and, possibly, triglycerides, glycerol Table 3 .
The increased release of 13 CO 2 during liver perfusion with [U- 13 C 6 ]glucose probably represents the sum of 13 CO 2 generated through the cytosolic pentose phosphate shunt and 13 CO 2 generated through mitochondrial PDH activity and the TCA cycle ( Figure 1) . Similarly, quantitatively significant amounts of 13 Clabelled lactate were generated from pyruvate and an increased flow of glucose carbon into alanine through transamination and into glutamate, possibly through reductive amination of 2-oxoglutarate ( Figure 4) . The perfused liver released these products of glycolysis within 3-5 min of adding GKA. It is important to note that the apparent decreased output of 13 C-labelled glutamate (nmol · min − 1 per g of wet mass) ( Figure 4B ) was not a result of decreased 13 C enrichment in glutamate isotopomers ( Figure 7A ). Rather, this decrease may result from increased transfer of the amino group from glutamate to form alanine. This explanation is supported by the increased output of 13 C-labelled alanine with GKA ( Figure 4A ), which is inversely correlated with decreased [
13 C]glutamate output. This pattern resembles the glucose-alanine cycle [36] . Additionally, the augmented availability of pyruvate probably increased acetyl-CoA production and incorporation of 13 C derived from glucose into the TCA cycle. This notion is evident from elevated cataplerosis of citrate, glutamate and aspartate ( Figures 5-7) , secondary to increased incorporation of 13 C-labelled pyruvate into the TCA cycle (anaplerosis).
An important question is how GKA increases flux through the TCA cycle. The present results with isolated hepatocytes demonstrate that GKA has no direct effect on the activity of PC or PDH, as is evident by unchanged release of 13 CO 2 or in the generation of 13 C mass isotopomer of aspartate, citrate or malate from 13 C-labelled pyruvate as precursor. Cumulatively, the data suggest that the significantly increased production of 13 CO 2 or 13 C-labelled mass isotopomers of citrate, malate, glutamate or aspartate from [U- 13 C 6 ]glucose during liver perfusion with GKA (Figures 3-7) is probably mediated entirely through elevated generation of 13 C-labelled pyruvate as an end product of glycolysis and its incorporation into the TCA cycle through an effective feedforward mechanism.
In addition to increased generation of 13 C-labelled glutamate and aspartate ( Figures 7A and 7B) , the results indicate that GKA also elevated the synthesis of serine and glycine secondary to stimulation of glycolysis. In addition, the results of the present study indicate increased synthesis of 13 C-labelled glutamine from 13 C-labelled glutamate ( Figure 7F ). In the liver, glutamine synthesis occurs mainly in the perivenous zone [34] . Previous studies show a significant GK activity in this region [34, 35] . It is possible that increased glycolysis by GKA and the resultant increased availability of glutamate and ATP ( Figure 7D and Table 1 ) led to activation of glutamine synthesis in perivenous hepatocytes.
The present study demonstrates for the first time that GKA stimulates the synthesis of NAG and ureagenesis ( Figure 9 ). This may be explained by the fact that GKA stimulated the generation of pyruvate and its metabolism to acetyl-CoA, thus furnishing more acetyl-CoA for NAG synthesis. In addition, the results demonstrate that the production of 13 C-labelled glutamate through the TCA cycle was significantly increased (Figure 7) . Together, increased mitochondrial levels of glutamate and acetylCoA, the precursors of NAG [12] , led to increased NAG synthesis, activation of carbamoylphosphate synthetase-I and greater mitochondrial citrulline synthesis [12, 37, 38] . The results of the present study are consistent with the concept that the synthesis of citrulline and urea is determined in large measure by NAG synthesis, with which the rate of ureagenesis is linearly correlated.
As discussed above, the results of the present study provide strong evidence supporting the conclusion that increased glycolysis is directly responsible for the widespread metabolic alterations that occurred in liver exposed to GKA. We base this conclusion on the following observations.
(i) In the present study, 5 mM [U- 13 C 6 ]glucose was infused at a rate of 3.5 ml · g − 1 · min − 1 , or 17 μmol · g − 1 · min − 1 . Assuming a glycogenolysis rate of 0.5 % · min − 1 [39] , glucose would be derived from glycogenolysis at approximately 1.5 μmol · g − 1 · min − 1 , or 8% of perfusate [U- 13 C 6 ]glucose (i.e. 1.5 compared with 17 μmol · g − 1 · min − 1 ). Indeed, the 13 C enrichment in the outflow [U- 13 C 6 ]glucose during 30-70 min of perfusion was approximately 90-94 MPE, with or without GKA, suggesting a minor dilution of perfusate [U- 13 C 6 ]glucose with unlabelled glucose coming from glycogenolysis.
(ii) Between 15 and 45 min of perfusion with or without GKA, there was little difference in O 2 consumption and outflow of 13 Clabelled metabolites (Figures 2-4) , or total and 15 N-urea output ( Figure 9 ). However, within 3-5 min of adding GKA (the latter was added to the perfusate at 45 min), there was a significant On the left-hand side are listed the potential benefits (i.e. glycogen synthesis, ammonia detoxification and improved energy balance), and on the right-hand side are given the potential risks of GKA (lactic acidosis, lipogenesis and the possibility of triglyceride accumulation in the liver). + , stimulation and/or increased generation; − , inhibition and/or decreased generation. The present findings demonstrate that the stimulation of glycolysis by GKA resulted in numerous changes in normal hepatic metabolism, including: (i) enhanced direct pathway of glycogen synthesis, but decreased gluconeogenesis; (ii) augmented anaplerosis and, associated with this, increased flux through the TCA cycle and generation of glutamate, aspartate or citrate (cataplerosis); (iii) the increased flux through the TCA may enhance the generation of NADH and thus ATP synthesis, resulting in an improved hepatic phosphorylation potential and energetic state; (iv) stimulated synthesis of NAG, and enhanced detoxification of NH 3 through ureagenesis; (v) increased generation and output of lactate, which could lead to lactic acidosis; and (vi) increased levels of citrate may augment hepatic lipogenesis and thus accumulation of triglycerides. OXA, oxaloacetate.
(P < 0.01) stimulation in the output of 13 CO 2 and 13 C-labelled lactate and alanine ( Figures 3 and 4 , Supplementary Figures S1 and S2, and Table 1 ). The increased outflow of 13 C-labelled metabolites was associated with augmented O 2 consumption in the perfusion with GKA ( Figure 2 ). In addition, experiments with isolated hepatocytes indicate that the addition of 3 μmol · l
Piragliatin activated GK and stimulated glycolysis ( Figure 10 ) in a manner similar to that observed in a liver perfusion system.
(iii) In both controls and perfusion with GKA, the 13 C enrichment (MPE) in 13 CO 2 , lactate and alanine in the outflow was increased within 5-10 min after the initiation of perfusion with [U-
13 C]glucose. Thereafter, the 13 C enrichment reached a steadystate ( Supplementary Figures S1 and S2) , suggesting that the intermediary metabolites were mainly derived from perfusate [U- 13 C]glucose, and that the metabolic differences between control and perfusion with GKA are a result of GK activation.
(iv) G6P is a key precursor for the 13 C-labelled metabolites presented in Figures 3-8 . At the end of perfusion, the average 13 C enrichment in M6 G6P was approximately 41 and 58 MPE and the sum of 13 C isotopomers of G6P was approximately 56 and 69 MPE, indicating that approximately 56 % and 69 % of the hepatic G6P pool was derived from perfusate [U- 13 C 6 ] glucose in control and perfusion with GKA respectively (Supplementary Table S1 at http://www.BiochemJ.org/bj/444/bj4440537add.htm). Furthermore, there is an apparent correlation between the levels of G6P (Table 3 ) and the synthesis and output of 13 C-labelled metabolites (Figures 5-7 and Table 1 ) as well as glycogen synthesis (Figure 8 ). Taken together, the results suggest that Piragliatin is responsible for increased generation of 13 C-labelled G6P and the resulting production of 13 C-labelled metabolites through various metabolic pathways (Figures 3-8 ). This conclusion is in accordance with a previous suggestion that G6P arising from the catalytic action of GK is responsible for the activation of liver glycogen synthesis in addition to providing a substrate for several other pathways [40] .
Implications of the results of the present study for the potential of GKAs in drug therapy of Type 2 diabetes
The results of the present study provide novel and deepened insights into the effects of Piragliatin on hepatic metabolism. Such information is essential in order to assess the therapeutic potential of this class of drugs. We emphasize that we did not study diabetic animals, but healthy rats in a postabsorptive state We therefore caution against facile extrapolation of our data to a liver that is either deprived of insulin or resistant to this hormone. Bearing this caveat in mind, the results of the present study support the following conclusions.
(i) Systemic glucose homoeostasis depends on the balance between hepatic glycolysis versus gluconeogenesis and glycogenesis versus glycogenolysis. The results of the present study demonstrate that the GKA decreased glycogen synthesis from 3-carbon precursors (i.e. pyruvate and lactate) and increased glycogen formed directly from glucose (Figure 8 ), suggesting reduced recycling of pyruvate back to glucose through gluconeogenesis. The notion that GKAs inhibit gluconeogenesis is supported by the results in Figure 10 and Supplementary Figure S5 . The conclusion that GKAs inhibited gluconeogenesis and augmented synthesis of glycogen is in agreement with a previous study demonstrating increased glycogenesis and lowered hepatic glucose production in Zucker diabetic rats following treatment with an adenovirus that directs the expression of hepatic GK [41] . Taken together, the results of the present study suggest that GKA modifies glucose homoeostasis by diminishing hepatic gluconeogenesis and stimulating the direct pathway of glycogenesis.
(ii) The present study provides the first evidence that GKAs enhance hepatic ureagenesis and thus ammonia detoxification. Hepatic urea synthesis is the only metabolic pathway capable of removing waste nitrogen. Liver metabolism in diabetes is profoundly impaired [1] [2] [3] [4] [5] , and hyperammonaemia may occur in Type 2 diabetes, a phenomenon noted in Zucker rats [42] . GKA may improve the detoxification of excess systemic ammonia through enhanced NAG and urea synthesis, and thus minimize metabolic complications and deleterious effects on the central nervous system secondary to diabetes.
(iii) GKA might cause lactic acidosis by causing overproduction of pyruvate. In contrast with β-cells, which have a relatively low activity of LDH [3] , hepatic parenchymal cells are rich in this enzyme. Production of lactate might then afford a 'sink' for excess generation of pyruvate. The marked stimulation of 13 Clabelled lactate outflow by the GKA (Figure 3C ) suggests that these drugs may cause lactic acidosis. In addition, the inhibition of gluconeogenesis by GKA (Figure 10 and Supplementary Figure  S5 ) may diminish hepatic metabolism of lactate and subsequently lead to elevation of systemic lactate. However, further in vivo study in normal and diabetic animals is required to examine this possibility.
(iv) The striking GKA stimulation of citrate production ( Figures 5B and 5E ) as well as glycerol 3-phosphate (Supplementary Figure S3) and triglycerides (Table 3 ) raises the possibility of increased hepatic lipogenesis as another liability of long-term treatment with this drug, as illustrated in Figure 11 . Citrate is a crucial intermediate and metabolic signal in the synthesis of cholesterol and complex lipids. In addition, previous studies showed that lipogenic genes are induced by G6P [43] , which is significantly elevated in liver perfused with GKA (Table 2 and Supplementary Figure S3) , again supporting the formulation that GKA augments hepatic lipogenesis. A relationship between activation of hepatic GK and increased synthesis of triglycerides is consistent with the finding that a higher GK can stimulate lipogenic genes [44] , a conclusion similar to that of other studies [43] [44] [45] [46] . However, we must emphasize that the present shortterm experiments with GKA indicate an insignificant elevation of triglycerides (Table 3) . Thus further long-term in vivo study in normal and diabetic animals is required to examine this possibility.
Conclusions and long-term perspectives
We found that the GKA Piragliatin causes widespread changes in hepatic metabolism in normal post-absorptive rats (Figure 11 ). The present study confirmed favourable therapeutic effects of GKA, such as stimulation of hepatic glycogenesis, inhibition of gluconeogenesis, improvement of the energy potential of liver tissue and facilitation of ammonia detoxification through ureagenesis. However, the results of the present study also identify lactic acidosis and/or fatty liver as potential risks of GKA treatment. Details of the dose-dependencies of these positive and negative actions of the GKA remain to be elucidated. Additional studies also may reveal whether it is feasible to dissociate these positive and negative effects. Studies also are needed in animals with diabetes of diverse aetiology in order to learn whether GKA effects on liver metabolism are similar to those we found in unaffected rats. In this regard, it is significant that long-term studies with haploinsufficient, mildly diabetic, GK-knockout mice fed a high-fat diet [47, 48] demonstrate that GKA can normalize hyperglycaemia without causing the side effects seen in the present study.
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SUPPLEMENTARY ONLINE DATA
Effects of a glucokinase activator on hepatic intermediary metabolism: study with 13 13 C at three carbons). Experimental details are as described in the legend to Figure S1 . Results are means + − S.D. for three independent liver perfusions per study group. M3 alanine isotopomer must have been derived from [U- 13 C]pyruvate, the product of [U-13 C]glucose glycolysis. As indicated in the legend to Figure S1 , these results demonstrate that the activation of GK by 3 μmol/l Piragliatin was directly responsible for the remarkable elevation of total and 13 C-labelled alanine output from the perfusate [U-
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13 C]glucose. Spectra demonstrate an approximately 2-fold higher peak of glycerol 3-phosphate (Gl3P) following perfusion with a GKA (B). In addition, the inset represents the expansion of the G6P peak at approximately 4.7 p.p.m., which was higher following perfusion with a GKA (B) compared with the control (A). PCh, phosphocholine; GPE, glycerophosphoryl ethanolamine; GPC, glycerophosphocholine.
Figure S4 Representative 13 C-NMR spectrum of freeze-clamped liver following perfusion without (A) or with (B) GKA
These spectra demonstrate remarkably higher peaks of 13 C isotopomers of lactate, alanine, serine, glycine, malate, glutamate, aspartate and glycogen in liver perfused with GKA (B) compared with control (A). Bet, betaine; Gluc, glucose; Lac, lactate; Glyc, C1-glucosyl (glycogen); Mal, malate; Succ, succinate.
